antiviral agent 38

2H-Pyrido[2',1':3,4]pyrazino[1,2-b]indazole-3-carboxylic acid, 6-(1, 1-Dimethylethyl)-6, 7-Dihydro-10 -(3-methoxypropoxy)-2-oxo-, (6R)- has antibacterial and antiviral activity and can be used to study Hepatitis B virus.

Antiviral agent 17 (Compound 4) is an anti-infection compound with strong antiviral effects, demonstrated by an EC50 of 0.015 μM in a human replicon assay, and effective against murine norovirus. It has potential applications in studying infectious and malignant diseases[1].

Antiviral agent is thiazolidin-4-one with anti-hepatitis B activity

Antiviral agent 34 is an orally available, potent antiviral compound that inhibits influenza A and B viruses.Antiviral agent 34 inhibits the proliferation of influenza viruses by modulating RNA polymerase.Antiviral agent 34 is used in the study of viral infections.

Antiviral agent 36 (compound 27), a potent inhibitor of both dengue (DENV) and Zika (ZIKV) viruses, demonstrates replication inhibition with EC50 values of 100 nM for ZIKV-FLR, 90 nM for ZIKV-HN16, 210 nM for DENV-2, and 120 nM for DENV-3 [1].

Antiviral agent 20 (Compound 17b) is a selective inhibitor of Zika virus (EC50: 4.5 μM) with low cytotoxicity.

Antiviral agent 14 is an antiviral compound that inhibits tobacco mosaic virus (TMV) with an EC50 of 135.5 μg mL and cucumber mosaic virus (CMV) with an EC50 of 178.6 μg mL.

Antiviral agent 7 is a peptide-based coating that effectively eliminates viruses.

Anticancer agent 38 (compound 19) is an aryl-urea compound, and is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC 50 of 5.2 μg/mL [1].

Antiviral agent 8, surpassing lead compounds crocin-1 and crocin-2, has been identified as a potent and promising candidate with enhanced antiviral activities.

Antifungal agent 38 is a heterocyclic disulfide with antifungal and antibacterial properties. It induces hyphal shrinkage, disrupts plasma membrane integrity, and causes cell content damage and leakage [1].

Antiviral agent 19 (Compound 3) is a selective inhibitor of the Zika virus (EC50: 1.3 μM) with low cytotoxicity.

Antiviral agent 25 (compound 6g), a novel non-peptide analog covalent inhibitor of SARS-CoV-2 3CL pro, exhibits robust inhibitory activity against both SARS-CoV-2 3CL pro and SARS-CoV-2 PL pro, with IC50 values of 0.118 µM and 0.448 µM, respectively. Furthermore, it demonstrates significant antiviral effects against SARS-CoV-2, achieving an EC50 value of 7.249 µM [1].

Antiviral agent 27 (Compound 12) exhibits significant activity against the Ebola virus, with an EC50 value of 14 nM [1].

Antiviral agent 18 (Compound 5) demonstrates significant antiviral activity against murine norovirus and holds potential for research in infectious and malignant diseases [1].

Antiviral agent 10 effectively inhibits the respiratory syncytial virus (RSV) [1], serving as a potent anti-viral compound.

Antitumor agent-38 is a highly effective antitumor compound that exhibits antiproliferative activity towards cancer cells. It induces cell cycle arrest specifically at the late S and G2 M phase, while not impeding microtubule formation or altering cell morphology [1].

Antiviral Agent 23, an effective inhibitor of enterovirus 71 (EV71) with an EC50 value of 94 nM, also exhibits potent suppression of METTL3/METTL14 activity. This compound is employed in the research of infections.

Antiproliferative Agent-38 (COM 18), a tetracyclic compound, features a reactive ring nitrogen (likely the quinoline moiety) that resists N-alkylation. Despite its classification, it neither exhibits anti-malarial properties nor inhibits cancer cell proliferation [1].

Antitubercular Agent-38, a derivative of Benzothiazinones (BTZs), demonstrates potent antituberculosis activity while maintaining low cardiac toxicity and minimal cell cytotoxicity [1]. This orally active compound is a promising therapeutic in the treatment of tuberculosis.

Antiviral agent 5 is a crucial intermediate utilized in the development of antiviral agents that specifically target 3C and 3CL proteases, which includes the SARS-CoV-2 M pro enzyme.

Antiviral agent 43 (compound 16) serves as a potent, orally active inhibitor of influenza A virus entry, demonstrating efficacy by inhibiting the replication of the influenza A strains VH04-H5N1 and PR8-H1N1 with EC50 values of 240 nM and 72 nM, respectively [1].

Antiviral agent 6 showed excellent anti-TSWV effects in vivo (EC50: 188 mg/L).

Antiviral agent 9 exhibits potent efficacy against HIV-1 with an EC50 value of 0.006 nM, indicating extremely low concentrations are sufficient to inhibit the virus. Additionally, it demonstrates a selectivity index (SI) nearly 300 times higher than that of tenofovir alafenamide fumarate (TAF), outlining its superior selectivity and potential safety profile.

Antiviral agent 51 (compound a), a potent fucoidan-based antiviral, interacts with DENV-2 RNA Dependant RNA polymerase (RdRp) [1].

Antiviral Agent 44 (compound 7b) exhibits anti-HCV activity in vitro [1].

Antiviralagent 56 (Compound 4) is an antiviral agent with anti-HIV activity.

Anti-inflammatory agent 38 (compound 23d) is a potent Nrf2/HO-1 pathway inhibitor, with an IC 50 value of 0.38 μM for NO . Nrf2/HO-1-IN-1 can significantly reduce the level of ROS in cells. Nrf2/HO-1-IN-1 can be used for researching anti-inflammatory [1] .

Antiviral agent 35 (compound 4d) is a potent oral inhibitor of the influenza virus, targeting early stages of viral replication. It suppresses influenza-induced ROS accumulation, autophagy, apoptosis, and the inflammatory response mediated by the RIG-1 pathway in a mouse model of pulmonary infection. Its cytotoxicity is minimal in MDCK cells, with a CC50 greater than 800 μM, and it has anti-H1N1 (A Weiss 43) activity with an EC50 of 2.28 μM [1].

Antiviral agent 46, also known as compound 4, is a cannabidiol (CBD) derivative exhibiting anti-SARS-CoV-2 activity (IC50: 1.90 μM) and ACE2 inhibition (IC50: 1.37 μM) [1].

Antiviralagent 57 (compound 81) is an antiviral drug that exhibits over 60% inhibition of ANO6 at a concentration of 50 nM.

Antiviral agent 33 (compound 1c), a double-stranded DNA (dsDNA) virus inhibitor, exhibits potent inhibitory activity with IC50 values of 0.0790 µM for VACV and 0.1572 µM for AdV5, and is a candidate for oral administration [1].

Antibacterial agent 38 is an effective antibacterial agent. It can be utilized in the scientific investigation of bacterial infections.

Antiviral Agent 30 (Example 118) is an active compound against HCV and RSV with an inhibitory concentration (IC 50) of greater than 25μM [1].

Nucleoside Derivatives - 6-Modified purine nucleosides; Drugs and Inhibitors

Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral activity, inhibiting the rabies virus (EC50: 1.45 μM) and pseudotyped SARS-CoV-2 (EC50: 14.6 μM).

Antiviralagent 58 (Compound J1) is an orally active antiviral agent that exhibits broad-spectrum activity against enveloped viruses. It effectively targets various pathogens, including Influenza A virus (IAV), Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Coronavirus OC43 (HCoV-OC43), and Herpes Simplex Virus types 1 and 2 (HSV-1 and HSV-2).

Zimet 38-74 is an agent of antiviral.